MKP1, VSMC, and Vascular Remodeling

Information

  • Research Project
  • 10206241
  • ApplicationId
    10206241
  • Core Project Number
    R01HL140954
  • Full Project Number
    5R01HL140954-04
  • Serial Number
    140954
  • FOA Number
    PA-16-160
  • Sub Project Id
  • Project Start Date
    1/1/2018 - 7 years ago
  • Project End Date
    7/31/2022 - 2 years ago
  • Program Officer Name
    CHEN, JUE
  • Budget Start Date
    8/1/2021 - 3 years ago
  • Budget End Date
    7/31/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    04
  • Suffix
  • Award Notice Date
    7/14/2021 - 3 years ago
Organizations

MKP1, VSMC, and Vascular Remodeling

Abstract Overwhelming evidence from previous studies suggests that vascular smooth muscle cells (VSMCs) plays a critical role in development of neointima hyperplasia and atherosclerosis but exact molecular mechanisms are poorly understood. We have obtained exciting preliminary data suggesting that down-regulation of mitogen-activated protein kinase phosphatase-1 (MKP-1) protein levels is associated with increased cell proliferation and stenosis in patients with atherosclerosis. Similarly, MKP-1 protein levels and neointimal hyperplasia are decreased in a mouse model of wire-mediated carotid artery injury. MKP-1 is known to suppress activation of signal transducer and activator of transcription (STAT1) signaling, a critical step leading to VSMC proliferation and neointimal hyperplasia. More importantly, MKP-1 overexpression is associated with decreased human aortic smooth muscle cell (HASMC) proliferation, STAT1 phosphorylation, and neointimal hyperplasia formation in response to vascular injury. With a concomitant reduction in MKP-1 expression, both liver kinase (LKB)1 activity and LKB1 phosphorylation at Ser428 is decreased in the carotid artery after wire-mediated injury. Further, LKB1 directly phosphorylates MKP-1 in a cell-free system, and overexpression of constitutively active LKB1 in LKB1-deficient A549 cells inhibits MKP-1 degradation. Finally, VSMC-specific LKB1 deletion mice exhibit lower levels of MKP-1 in mouse aortas and exacerbated neointimal hyperplasia and atherosclerosis. Thus we hypothesize that LKB1-regulated MKP-1 suppresses VSMC proliferation, migration, neointimal formation, and atherosclerosis through the inhibition of STAT1 signaling. The goals of the present application are to characterize the mechanism by which LKB1 via MKP-1 suppresses VSMC proliferation, intimal hyperplasia, atherosclerosis, and determine whether the effect of MKP-1 is mediated through the inhibition of STAT1 signaling, which has been shown to promote VSMC proliferation and intimal hyperplasia (1) and impair thrombus resolution (2) and wound healing (3). Defining the roles of LKB1 in the regulation of VSMC proliferation, intimal hyperplasia, and atherosclerosis may identify potential targets for the treatment of atherothrombotic vascular diseases.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R01
  • Administering IC
    HL
  • Application Type
    5
  • Direct Cost Amount
    453953
  • Indirect Cost Amount
    233786
  • Total Cost
    687739
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    837
  • Ed Inst. Type
    ORGANIZED RESEARCH UNITS
  • Funding ICs
    NHLBI:687739\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    GEORGIA STATE UNIVERSITY
  • Organization Department
    MISCELLANEOUS
  • Organization DUNS
    837322494
  • Organization City
    ATLANTA
  • Organization State
    GA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    303023999
  • Organization District
    UNITED STATES